Compare ONMD & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONMD | LSTA |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 20.9M |
| IPO Year | N/A | N/A |
| Metric | ONMD | LSTA |
|---|---|---|
| Price | $1.34 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 2.3M | 23.6K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $494,000.00 | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $1.81 |
| 52 Week High | $4.22 | $4.20 |
| Indicator | ONMD | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 47.86 |
| Support Level | $1.24 | $2.00 |
| Resistance Level | $1.54 | $2.17 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 16.67 | 52.00 |
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's technology has provens the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade, image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols, paving the way for Real World Evidence.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.